Molbio Diagnostics Ltd has opened its initial public offering for subscription on the Mainboard of both BSE and NSE, with the issue live from 10 August 2026 to 12 August 2026 at a price band of ₹768–₹807. Notably, there has been no anchor investor allotment reported for this issue.
Based in Verna, Goa, Molbio Diagnostics is a pioneering medical diagnostics company that develops point‑of‑care molecular testing solutions. Its flagship Truenat platform is a portable real‑time PCR system designed for rapid and accurate detection of infectious diseases including tuberculosis, HIV and hepatitis — a solution that has gained global recognition for enhancing diagnostic access in decentralized healthcare settings.
| Opens | 10 Aug 2026 |
| Closes | 12 Aug 2026 |
| Price Band | ₹768–₹807 |
| Lot Size | 18 shares |
No anchor investor allotment has been reported for this issue - this is typical for SME IPOs, which do not always carry an anchor round.
Follow live GMP and subscription numbers on the Molbio Diagnostics Ltd IPO page while the issue is open.